Danish Agency To Buy New Pharmacovigilance System
DMA Under Pressure To Comply With Deadline For Mandatory E2B(R3) Format
Rather than develop a new drug safety monitoring system from scratch, the Danish Medicines Agency is looking for a readymade solution.
You may also be interested in...
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.